GlassScriptPhysician profile
Ravi Menghani
NPI 1518285360
$2,642.12
in general payments reported to CMS, 2019-2025
24 companies · $781 in 2025
The $781 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $260 · 2021: $130 · 2022: $486 · 2023: $164 · 2024: $404 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $519.89 | 2020-2025 | Cequa |
| Alcon Vision LLC | $415.25 | 2019-2025 | Rocklatan, Hydrus Microstent, Tryptyr |
| Mallinckrodt Hospital Products INC. | $235.76 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $216.16 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $178.13 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $161.73 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $123.53 | 2019-2022 | |
| Amgen INC. | $92.59 | 2024-2025 | Tepezza |
| Dompe US, INC. | $92.43 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $85.78 | 2025 | Vevye |
| Allergan, INC. | $73.40 | 2020-2021 | |
| Oyster Point Pharma, INC. | $64.22 | 2022 | |
| Abbvie INC. | $59.45 | 2023 | |
| Thea Pharma INC. | $47.37 | 2024-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.70 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $41.65 | 2025 | Miebo, Vyzulta, Xiidra |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Rayner Intraocular Lenses Limited | $28.11 | 2024 | Rayone Emv, Rayone Aspheric, Omidria |
| Horizon Therapeutics Plc | $27.22 | 2022 | |
| Shire North American Group INC | $25.00 | 2019 | |
| Kala Pharmaceuticals, INC. | $24.11 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $20.07 | 2021 | |
| Optos, INC. | $13.91 | 2020 | |
| Ani Pharmaceuticals, INC. | $13.86 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Menghani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.